27 October 2025
Merck's WINREVAIR Approved by FDA for Expanded PAH Treatment
WINREVAIR, now approved for PAH, improves exercise capacity, reduces clinical worsening risks, and shows significant efficacy in the ZENITH trial. Monitor hemoglobin and platelets during treatment.